304 related articles for article (PubMed ID: 34022371)
1. The current second wave and COVID-19 vaccination status in India.
Chakraborty C; Sharma AR; Bhattacharya M; Agoramoorthy G; Lee SS
Brain Behav Immun; 2021 Aug; 96():1-4. PubMed ID: 34022371
[TBL] [Abstract][Full Text] [Related]
2. Fake COVID-19 vaccines: scams hampering the vaccination drive in India and possibly other countries.
Choudhary OP; Priyanka ; Singh I; Mohammed TA; Rodriguez-Morales AJ
Hum Vaccin Immunother; 2021 Nov; 17(11):4117-4118. PubMed ID: 34357851
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study.
Desai D; Khan AR; Soneja M; Mittal A; Naik S; Kodan P; Mandal A; Maher GT; Kumar R; Agarwal A; Gowda NR; H V; Kumar P; Pandey S; Pandey RM; Kumar A; Ray A; Jorwal P; Nischal N; Choudhary A; Brijwal M; Madan K; Lodha R; Sinha S; Dar L; Wig N; Guleria R
Lancet Infect Dis; 2022 Mar; 22(3):349-356. PubMed ID: 34826383
[TBL] [Abstract][Full Text] [Related]
4. Impact of second wave of COVID-19 pandemic on the hesitancy and refusal of COVID-19 vaccination in Puducherry, India: a longitudinal study.
Anandraj J; Krishnamoorthy Y; Sivanantham P; Gnanadas J; Kar SS
Hum Vaccin Immunother; 2021 Dec; 17(12):5024-5029. PubMed ID: 34847815
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 variants in India: Potential role in second wave and impact on vaccination.
Kunal S; Aditi ; Gupta K; Ish P
Heart Lung; 2021; 50(6):784-787. PubMed ID: 34217989
[No Abstract] [Full Text] [Related]
6. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
7. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine preferences in India.
Bansal P; Raj A; Mani Shukla D; Sunder N
Vaccine; 2022 Apr; 40(15):2242-2246. PubMed ID: 35282928
[TBL] [Abstract][Full Text] [Related]
9. Will COVID-19 vaccine equity be possible in India?
Mathivathanan K
Vaccine; 2021 Aug; 39(35):4928-4929. PubMed ID: 34330556
[No Abstract] [Full Text] [Related]
10. COVID-19 vaccination strategies and policies in India: The need for further re-evaluation is a pressing priority.
Rackimuthu S; Hasan MM; Bardhan M; Essar MY
Int J Health Plann Manage; 2022 May; 37(3):1847-1850. PubMed ID: 34510541
[TBL] [Abstract][Full Text] [Related]
11. Benign cutaneous reactions post-COVID-19 vaccination: A case series of 16 patients from a tertiary care center in India.
Agarwal A; Panda M; Behera BK; Jena AK
J Cosmet Dermatol; 2022 Jan; 21(1):30-33. PubMed ID: 34762355
[No Abstract] [Full Text] [Related]
12. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
13. COVID 19 vaccination of persons with schizophrenia in India - Need for imperative action!
Suhas S
Schizophr Res; 2021 May; 231():49-50. PubMed ID: 33752107
[No Abstract] [Full Text] [Related]
14. Coronavirus disease 2019 vaccination in patients with psoriasis: A position statement from India by SIG psoriasis (IADVL Academy).
Parthasaradhi A; Ganguly S; Kar BR; Thomas J; Neema S; Tahiliani S; Sathishkumar D; Parasramani SG; Chalam KV; Komeravalli H
Indian J Dermatol Venereol Leprol; 2022; 88(3):286-290. PubMed ID: 35434988
[TBL] [Abstract][Full Text] [Related]
15. Second wave of COVID-19 in India: Dissection of the causes and lessons learnt.
Choudhary OP; Priyanka ; Singh I; Rodriguez-Morales AJ
Travel Med Infect Dis; 2021; 43():102126. PubMed ID: 34144178
[No Abstract] [Full Text] [Related]
16. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
17. Challenges facing COVID-19 vaccination in India: Lessons from the initial vaccine rollout.
Pandey A; Sah P; Moghadas SM; Mandal S; Banerjee S; Hotez PJ; Galvani AP
J Glob Health; 2021 Jun; 11():03083. PubMed ID: 34221355
[No Abstract] [Full Text] [Related]
18. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
19. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
Yang W; Shaman J
medRxiv; 2021 Nov; ():. PubMed ID: 34845460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
